© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Genitourinary Cancers | Clinical
Carducci Recommends Weighing QOL, Survival Benefit When Selecting Therapy for Second-line or Later CRPC
November 24, 2020
Michael A. Carducci, MD, provided recommendations for treatment of a 75-year-old man with castrastion-resistant prostate cancer.
Further Research Required to Find Biomarkers for Urothelial Cancer
November 20, 2020
Petros Grivas, MD, PhD, discusses the phase 3 KEYNOTE-045 trial and the association between gene expression signatures and pembrolizumab in patients with advanced urothelial cancer.
UGN-102 Presents as a Surgical Alternative for Low-Grade Intermediate Risk NMIBC
November 17, 2020
Durable responses were shown with the investigational agent UGN-102 as treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer, according to final results of the phase 2b OPTIMA II study .
Countless Options to Improve Future Outcomes in Subgroups of Patients With GU Cancers
October 30, 2020
In genitourinary cancers, presentation of subgroup analysis data from large randomized clinical trials demonstrated findings that will change practice for oncologists who treat patients with prostate cancer, bladder cancer, and renal cell carcinoma.
CheckMate-9ER Proves to be Efficacious in Advanced or Metastatic RCC
October 09, 2020
Neeraj Agarwal, MD, discusses the efficacy of nivolumab and cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma in the phase 3 CheckMate-9ER trial.
CheckMate-9ER Shows Efficacy of Nivolumab/Cabozantinib Combo in RCC
September 25, 2020
Bradley McGregor, MD, discusses the CheckMate-9ER trial of nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
Investigators Examine Biomarkers of Response to Avelumab in Urothelial Carcinoma
September 20, 2020
Biomarkers of immune activity were linked with overall survival benefit to frontline maintenance avelumab in patients with advanced urothelial cancer, according to data presented at the ESMO Virtual Congress 2020 from an exploratory analysis of the phase 3 JAVELIN Bladder 100 trial.
Sacituzumab Govitecan Sustains Clinical Activity in Patients With Heavily Pretreated mUC
September 20, 2020
Final results from cohort 1 of the phase 3 TROPHY-U-01 trial reported continued significant activity with sacituzumab govitecan-hziy as treatment of patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.
Statistical Analyses Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC
May 31, 2020
Stratified multivariate analysis as well as efficacy from multiple treatment time points confirmed the benefit of cabazitaxel over abiraterone acetate or enzalutamide as a standard treatment in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents, according to results presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program.
DFS Improvement Falls Short With Anti–PD-L1 in Muscle-Invasive Urothelial Cancer
May 31, 2020
"Irrespective of the PD-L1 status, there were no trends in favor of atezolizumab in both arms."